Abbott secures CE mark for first dual glucose‑ketone diabetes sensor

Abbott announced that its new dual glucose‑ketone sensing technology has received CE marking. The CE mark confirms compliance with European health‑device regulations. This approval makes the device the first of its kind for diabetes monitoring in Europe. The technology enables simultaneous measurement of glucose and ketone levels. Abbott (ticker ABT) expects the sensor to improve patient management of diabetes. The clearance paves the way for commercial launch pending final steps. Industry analysts view the development as a significant advancement in diabetes care. Market observers will watch how the device is adopted after approval.